Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BMS-986253 |
Trade Name | |
Synonyms | HuMax-IL8|MDX 018|MDX-018|BMS986253|BMS- 86253 |
Drug Descriptions |
BMS-986253 (HuMax-IL8) is a monoclonal antibody that targets interleukin-8 (CXCL8, IL8) to prevent activation of the receptors, CXCR1 and CXCR2, in effort to prevent immune escape and tumor progression (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3091-3091). |
DrugClasses | |
CAS Registry Number | 2231258-73-2 |
NCIT ID | C124227 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BMS-986253 | BMS-986253 | 0 | 2 |
BMS-986253 + Cabiralizumab | BMS-986253 Cabiralizumab | 0 | 0 |
BMS-986253 + Decitabine and Cedazuridine | BMS-986253 Decitabine and Cedazuridine | 0 | 1 |
BMS-986253 + Degarelix + Nivolumab | BMS-986253 Degarelix Nivolumab | 0 | 1 |
BMS-986253 + Nivolumab | BMS-986253 Nivolumab | 0 | 6 |